Biodesix raises $22M in series F

Molecular diagnostics company Biodesix Inc. (Boulder, Colo.) said it raised $22 million in a series F round from undisclosed investors. Existing investors provided the majority of the funds.

The company said it would develop new diagnostic tests, including its BDX008 assay to predict the response of melanoma patients to an anti- PD-1 immunotherapy. Director of Corporate Marketing Rachel Berry told BioCentury the company expects to release data in 2H16 related to the blood-based proteomic test. ...